SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 249 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,116 | -56.2% | 200 | 0.0% | 0.00% | -60.0% |
Q2 2023 | $9,404 | +12.1% | 200 | 0.0% | 0.01% | 0.0% |
Q1 2023 | $8,392 | +10.0% | 200 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $7,628 | -4.6% | 200 | 0.0% | 0.01% | -16.7% |
Q3 2022 | $8,000 | +33.3% | 200 | 0.0% | 0.01% | +50.0% |
Q2 2022 | $6,000 | -14.3% | 200 | 0.0% | 0.00% | -20.0% |
Q1 2022 | $7,000 | -22.2% | 200 | 0.0% | 0.01% | -16.7% |
Q4 2021 | $9,000 | 0.0% | 200 | 0.0% | 0.01% | -14.3% |
Q3 2021 | $9,000 | -18.2% | 200 | 0.0% | 0.01% | -22.2% |
Q2 2021 | $11,000 | -26.7% | 200 | 0.0% | 0.01% | -30.8% |
Q1 2021 | $15,000 | -11.8% | 200 | 0.0% | 0.01% | -23.5% |
Q4 2020 | $17,000 | – | 200 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |